These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1852896)

  • 21. [Prostaglandin E1 in therapy of peripheral arterial occlusive disease].
    Sinzinger H; Rogatti W
    Wien Klin Wochenschr; 1991; 103(18):558-65. PubMed ID: 1750223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
    Böger RH; Bode-Böger SM; Thiele W; Creutzig A; Alexander K; Frölich JC
    J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma prostaglandin E1 concentrations and hemodynamics during intravenous infusions of prostaglandin E1 in humans and swine.
    Awas JA; Soteriou MC; Drougas JG; Stokes KA; Roberts LJ; Pinson CW
    Transplantation; 1996 Jun; 61(11):1624-9. PubMed ID: 8669108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
    Thum J; Caspary L; Creutzig A; Alexander K
    Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training.
    Scheffler P; de la Hamette D; Gross J; Mueller H; Schieffer H
    Circulation; 1994 Aug; 90(2):818-22. PubMed ID: 8044953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
    Heidrich H
    Vasa Suppl; 1991; 33():346-7. PubMed ID: 1788752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostaglandin E1 produces spasmolytic effects on histamine-induced bronchoconstriction in dogs.
    Hashimoto Y; Hirota K; Ohtomo N; Sato T; Ishihara H; Matsuki A
    Crit Care Med; 1999 Dec; 27(12):2755-9. PubMed ID: 10628622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutrophil function in peripheral arterial occlusive disease: the effects of prostaglandin E1.
    Weiss T; Eckstein H; Weiss C; Diehm C
    Vasc Med; 1998; 3(3):171-5. PubMed ID: 9892509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Iontophoretic application of prostaglandin E1 for improvement in peripheral microcirculation.
    Saeki S; Yamamura K; Matsushita M; Nishikimi N; Sakurai T; Nimura Y
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):525-9. PubMed ID: 9799055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome.
    Cox JW; Andreadis NA; Bone RC; Maunder RJ; Pullen RH; Ursprung JJ; Vassar MJ
    Am Rev Respir Dis; 1988 Jan; 137(1):5-12. PubMed ID: 3337471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
    Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
    Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic efficacy of intravenously applied prostaglandin E1.
    Scheffler P; de la Hamette D; Leipnitz G
    Vasa Suppl; 1989; 28():19-25. PubMed ID: 2609240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endothelial function in patients with peripheral vascular disease: influence of prostaglandin E1.
    Weiss T; Fischer D; Hausmann D; Weiss C
    Prostaglandins Leukot Essent Fatty Acids; 2002 Nov; 67(5):277-81. PubMed ID: 12445486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omega-hydroxylation of prostaglandin E1 in the isolated perfused lungs of pregnant rabbits.
    Leithauser MT; Roerig DL; Winquist SM; Gee A; Okita RT; Masters BS
    Prostaglandins; 1988 Dec; 36(6):819-33. PubMed ID: 3244833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacologic concepts for clinical use of prostaglandin E1].
    Schrör K
    Vasa Suppl; 1991; 33():335-6. PubMed ID: 1788746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosynthesis of a novel prostaglandin, delta 17-PGE1, in the ram.
    Oliw EH; Sprecher H; Hamberg M
    Acta Physiol Scand; 1986 May; 127(1):45-9. PubMed ID: 3728046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of intravenous prostaglandin E1 on arterial compliance: a randomized controlled trial.
    Mlekusch W; Schillinger M; Sabeti S; Al-Awami M; Gschwandtner M; Minar E
    Vasa; 2004 Aug; 33(3):131-6. PubMed ID: 15461064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
    Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
    Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
    Matsui K; Ikeda U; Murakami Y; Yoshioka T; Shimada K
    Am Heart J; 2003 Feb; 145(2):330-3. PubMed ID: 12595852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostaglandin E1 incorporated in lipid microspheres (lipo PGE1).
    Otomo S; Mizushima Y; Aihara H; Yokoyama K; Watanabe M; Yanagawa A
    Drugs Exp Clin Res; 1985; 11(9):627-31. PubMed ID: 3880049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.